| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Bismuth subcarbonate does not have a specific molecular target. It acts locally in the gastrointestinal tract, where it provides a protective coating over ulcers and inflamed tissues, and may have mild antimicrobial activity. Its major use is as an opaque substance placed in the digestive tract to show up on X-rays.
|
|---|---|
| ln Vitro |
In vitro activity of bismuth subcarbonate is related to its physicochemical properties rather than specific biological activity. It is practically insoluble in water and is used as an opacifier and protective agent. The compound's ability to form a protective coating over inflamed tissues can be demonstrated in vitro using models of mucosal surfaces.
|
| ln Vivo |
In vivo activity of bismuth subcarbonate includes its use as a gastrointestinal protective agent and as an opacifier for X-ray diagnostics. It helps to allay diarrhea and provides mechanical protection to inflamed mucous membranes and ulcers. The compound is administered orally and acts locally in the gastrointestinal tract.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not performed for bismuth subcarbonate, as it is not a pharmacologically active compound with specific molecular targets. Its characterization involves physicochemical analysis, such as solubility testing, particle size analysis, and determination of heavy metal content.
|
| Cell Assay |
In vitro cellular assays are not applicable to bismuth subcarbonate, as it acts locally in the gastrointestinal tract rather than through cellular mechanisms. Its protective effects are mechanical rather than pharmacological, and its use as an opacifier is based on its radiopacity.
|
| Animal Protocol |
In vivo animal experiments for bismuth subcarbonate have been conducted to evaluate its use as a gastrointestinal protective agent and as an opacifier for X-ray diagnostics. The compound is administered orally to animals, and its effects on gastrointestinal inflammation and ulcer healing are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for bismuth subcarbonate indicate that it is practically insoluble in water and is not significantly absorbed from the gastrointestinal tract. It acts locally and is excreted in the feces. Its lack of systemic absorption contributes to its safety profile for gastrointestinal use.
|
| Toxicity/Toxicokinetics |
Bismuth subcarbonate is generally considered safe for its intended uses. It is not significantly absorbed from the gastrointestinal tract, minimizing systemic toxicity. However, it may cause long-lasting harmful effects to aquatic life. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Chenmin Xu, et al. Bismuth Subcarbonate with Designer Defects for Broad-Spectrum Photocatalytic Nitrogen Fixation. ACS Appl Mater Interfaces. 2018 Aug 1;10(30):25321-25328.
[2]. Rimsha Ali, et al. Milk-Alkali Syndrome. StatPearls [Internet]. 2021 Jan. |
| Additional Infomation |
Bismuth carbonate is a bismuth coordination compound, belonging to the one-carbon compound family. Functionally, it is related to carbonic acid.
See also: Bismuth cations (containing active groups)... See more... Bismuth subcarbonate (Bismuth carbonate oxide) (CAS#: 5892-10-4) has the empirical formula (BiO)2CO3 and a molecular weight of 509.97-510.01 g/mol. It is a white powder used as a gastrointestinal protectant, antidiarrheal agent, and radiographic opacifier. |
| Molecular Formula |
CBI2O5
|
|---|---|
| Molecular Weight |
509.97
|
| Exact Mass |
509.935
|
| CAS # |
5892-10-4
|
| PubChem CID |
16683095
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
6.86 g/mL at 25 °C(lit.)
|
| Boiling Point |
333.6ºC at 760mmHg
|
| Melting Point |
308(分解)ºC
|
| Flash Point |
169.8ºC
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
97
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Bi](=O)OC(=O)O[Bi]=O
|
| InChi Key |
MGLUJXPJRXTKJM-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/CH2O3.2Bi.2O/c2-1(3)4;;;;/h(H2,2,3,4);;;;/q;2*+1;;/p-2
|
| Chemical Name |
bis(oxobismuthanyl) carbonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : < 1 mg/mL
Ethanol : < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9609 mL | 9.8045 mL | 19.6090 mL | |
| 5 mM | 0.3922 mL | 1.9609 mL | 3.9218 mL | |
| 10 mM | 0.1961 mL | 0.9804 mL | 1.9609 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
